NEW YORK (GenomeWeb) – Biocept announced today it has priced a public offering expected to raise approximately $10 million in gross proceeds.

Biocept is offering 9.1 million shares of its common stock, as well as warrants to purchase up to an aggregate of 9.1 million shares at a combined offering price of $1.10 per share. The warrants are exercisable immediately and will expire five years from the date of issuance, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

ScienceInsider reports that a new security policy at the US Food and Drug Administration may prevent foreign nationals from working there.

WBUR in Boston looks into Orig3n's genetic fitness assessments to find more research is needed.

Cleveland.com reports that getting a DNA profile removed from a law enforcement database can be tricky.

In PNAS this week: de novo mutations contribute to non-syndromic craniosynostosis, fungal tree of life, and more.